Alzinova AB, a Swedish biopharma company developing disease-modifying treatments for Alzheimer’s, announces that the manufacturing process for its oligomer-specific vaccine, ALZ-101, has been further improved to facilitate large-scale production.
March 30, 2022
· 2 min read
